Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascariasis | 5 | 2021 | 68 | 2.340 |
Why?
|
| Helminths | 4 | 2022 | 46 | 2.120 |
Why?
|
| Helminthiasis | 4 | 2020 | 77 | 1.920 |
Why?
|
| Anthelmintics | 3 | 2020 | 55 | 1.380 |
Why?
|
| Hypersensitivity | 3 | 2022 | 183 | 1.370 |
Why?
|
| Emigrants and Immigrants | 3 | 2020 | 143 | 1.320 |
Why?
|
| Anemia | 2 | 2021 | 339 | 1.110 |
Why?
|
| Coinfection | 2 | 2020 | 169 | 1.100 |
Why?
|
| Hookworm Infections | 2 | 2020 | 124 | 1.090 |
Why?
|
| Dog Diseases | 2 | 2023 | 50 | 0.950 |
Why?
|
| Ascaris suum | 2 | 2021 | 29 | 0.910 |
Why?
|
| Toxocariasis | 2 | 2023 | 27 | 0.880 |
Why?
|
| Cat Diseases | 1 | 2023 | 15 | 0.860 |
Why?
|
| Leishmaniasis | 2 | 2022 | 33 | 0.820 |
Why?
|
| Antiprotozoal Agents | 1 | 2022 | 37 | 0.810 |
Why?
|
| Noncommunicable Diseases | 1 | 2022 | 15 | 0.800 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2022 | 48 | 0.800 |
Why?
|
| Leishmania | 1 | 2022 | 29 | 0.800 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2021 | 30 | 0.750 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 62 | 0.730 |
Why?
|
| Eosinophilia | 1 | 2022 | 101 | 0.730 |
Why?
|
| Trichinella | 1 | 2020 | 2 | 0.720 |
Why?
|
| Prednisone | 1 | 2021 | 275 | 0.710 |
Why?
|
| Trichinellosis | 1 | 2020 | 14 | 0.710 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2020 | 14 | 0.710 |
Why?
|
| Health Communication | 1 | 2020 | 25 | 0.710 |
Why?
|
| Maternal Health | 1 | 2020 | 20 | 0.700 |
Why?
|
| Travel | 1 | 2021 | 115 | 0.700 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2020 | 25 | 0.690 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 71 | 0.690 |
Why?
|
| Malaria | 1 | 2020 | 85 | 0.670 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 176 | 0.640 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 140 | 0.620 |
Why?
|
| West Nile virus | 2 | 2023 | 117 | 0.610 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 606 | 0.610 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 52 | 0.600 |
Why?
|
| West Nile Fever | 2 | 2023 | 139 | 0.590 |
Why?
|
| Giardiasis | 2 | 2017 | 10 | 0.590 |
Why?
|
| Lung Diseases | 1 | 2021 | 383 | 0.580 |
Why?
|
| Giardia lamblia | 1 | 2017 | 10 | 0.560 |
Why?
|
| Ascaris lumbricoides | 1 | 2017 | 19 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.530 |
Why?
|
| Antiviral Agents | 1 | 2021 | 748 | 0.510 |
Why?
|
| Vaccination | 2 | 2020 | 953 | 0.510 |
Why?
|
| Enterobiasis | 1 | 2015 | 3 | 0.500 |
Why?
|
| Coccidioidomycosis | 1 | 2015 | 12 | 0.490 |
Why?
|
| Lung | 3 | 2021 | 1491 | 0.490 |
Why?
|
| Meningitis, Viral | 1 | 2015 | 10 | 0.480 |
Why?
|
| Trichuriasis | 1 | 2015 | 31 | 0.480 |
Why?
|
| Encephalitis, Viral | 1 | 2015 | 20 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.470 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 947 | 0.450 |
Why?
|
| Aging | 1 | 2020 | 1182 | 0.430 |
Why?
|
| United States | 9 | 2023 | 10887 | 0.420 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 181 | 0.410 |
Why?
|
| Pandemics | 1 | 2020 | 1099 | 0.400 |
Why?
|
| Clostridium chauvoei | 1 | 2011 | 1 | 0.380 |
Why?
|
| Animals | 12 | 2023 | 34072 | 0.380 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2011 | 2 | 0.380 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 336 | 0.370 |
Why?
|
| Humans | 24 | 2023 | 124596 | 0.370 |
Why?
|
| Larva | 3 | 2021 | 245 | 0.370 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 375 | 0.360 |
Why?
|
| Zoonoses | 2 | 2023 | 44 | 0.340 |
Why?
|
| Public Health | 2 | 2023 | 262 | 0.330 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 1003 | 0.320 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 298 | 0.320 |
Why?
|
| Cost of Illness | 3 | 2022 | 245 | 0.310 |
Why?
|
| Child | 9 | 2023 | 24375 | 0.310 |
Why?
|
| Clostridium Infections | 1 | 2011 | 245 | 0.290 |
Why?
|
| Cats | 2 | 2023 | 118 | 0.240 |
Why?
|
| Dogs | 2 | 2023 | 768 | 0.230 |
Why?
|
| Endemic Diseases | 2 | 2015 | 55 | 0.220 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 122 | 0.210 |
Why?
|
| Albendazole | 2 | 2020 | 29 | 0.200 |
Why?
|
| Immunity | 2 | 2020 | 191 | 0.200 |
Why?
|
| Leukocyte Count | 1 | 2022 | 250 | 0.190 |
Why?
|
| Th2 Cells | 2 | 2021 | 185 | 0.190 |
Why?
|
| Eosinophils | 1 | 2022 | 120 | 0.190 |
Why?
|
| Morbidity | 1 | 2022 | 247 | 0.190 |
Why?
|
| Iran | 1 | 2021 | 69 | 0.190 |
Why?
|
| Female | 10 | 2021 | 66485 | 0.180 |
Why?
|
| Candida albicans | 1 | 2021 | 76 | 0.180 |
Why?
|
| Child, Preschool | 5 | 2020 | 14009 | 0.180 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 22 | 0.180 |
Why?
|
| Unemployment | 1 | 2020 | 20 | 0.170 |
Why?
|
| Ancylostomatoidea | 1 | 2020 | 59 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3424 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 196 | 0.170 |
Why?
|
| Candidiasis | 1 | 2021 | 129 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2020 | 81 | 0.170 |
Why?
|
| Medically Underserved Area | 1 | 2020 | 89 | 0.170 |
Why?
|
| Middle Aged | 6 | 2021 | 26714 | 0.170 |
Why?
|
| Housing | 1 | 2020 | 59 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 90 | 0.170 |
Why?
|
| Male | 8 | 2021 | 61192 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2020 | 427 | 0.160 |
Why?
|
| Skin | 1 | 2022 | 520 | 0.160 |
Why?
|
| Interleukin-10 | 2 | 2018 | 172 | 0.160 |
Why?
|
| Food Supply | 1 | 2020 | 101 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 254 | 0.160 |
Why?
|
| Ascaris | 1 | 2018 | 9 | 0.160 |
Why?
|
| Health Education | 1 | 2020 | 220 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2021 | 327 | 0.150 |
Why?
|
| Interleukin-5 | 1 | 2018 | 43 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2020 | 4795 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 178 | 0.150 |
Why?
|
| Interleukin-4 | 1 | 2018 | 139 | 0.150 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 770 | 0.150 |
Why?
|
| Protective Agents | 1 | 2018 | 32 | 0.150 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 149 | 0.150 |
Why?
|
| Ovalbumin | 1 | 2018 | 318 | 0.150 |
Why?
|
| Interleukin-13 | 1 | 2018 | 97 | 0.150 |
Why?
|
| Health Policy | 1 | 2020 | 213 | 0.150 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 25 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2020 | 375 | 0.140 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 30 | 0.140 |
Why?
|
| Ecuador | 1 | 2017 | 11 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2021 | 1185 | 0.140 |
Why?
|
| Risk Factors | 2 | 2022 | 10270 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 866 | 0.140 |
Why?
|
| Poverty | 1 | 2020 | 422 | 0.140 |
Why?
|
| Hygiene Hypothesis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Interleukin-12 | 1 | 2017 | 115 | 0.130 |
Why?
|
| Interleukin-2 | 1 | 2017 | 227 | 0.130 |
Why?
|
| Onchocerca | 1 | 2015 | 5 | 0.130 |
Why?
|
| Cytokines | 1 | 2021 | 1290 | 0.130 |
Why?
|
| Onchocerciasis | 1 | 2015 | 20 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 429 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 777 | 0.120 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2015 | 63 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2017 | 502 | 0.120 |
Why?
|
| Mice | 3 | 2021 | 17630 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 237 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 428 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 681 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 240 | 0.110 |
Why?
|
| Young Adult | 2 | 2020 | 9014 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 251 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2020 | 657 | 0.110 |
Why?
|
| Feces | 1 | 2017 | 725 | 0.110 |
Why?
|
| Developing Countries | 1 | 2015 | 270 | 0.110 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 215 | 0.100 |
Why?
|
| Antiparasitic Agents | 1 | 2013 | 31 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 560 | 0.100 |
Why?
|
| Parasitic Diseases | 1 | 2013 | 61 | 0.100 |
Why?
|
| Adult | 3 | 2020 | 29438 | 0.090 |
Why?
|
| Adolescent | 3 | 2020 | 19280 | 0.090 |
Why?
|
| Biomarkers | 1 | 2020 | 3063 | 0.090 |
Why?
|
| Taxoids | 1 | 2011 | 67 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1322 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 355 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 369 | 0.080 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 478 | 0.080 |
Why?
|
| Asthma | 1 | 2016 | 749 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4350 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7179 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2021 | 12322 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2022 | 16314 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6533 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 822 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 91 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2498 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 691 | 0.040 |
Why?
|
| Swine Diseases | 1 | 2018 | 37 | 0.040 |
Why?
|
| Antibodies, Helminth | 1 | 2018 | 125 | 0.040 |
Why?
|
| Antigens, Helminth | 1 | 2018 | 190 | 0.030 |
Why?
|
| Immunization | 1 | 2018 | 307 | 0.030 |
Why?
|
| Aged | 1 | 2015 | 19703 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 381 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 1151 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2015 | 42 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 133 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1176 | 0.030 |
Why?
|
| Vaccines | 1 | 2018 | 366 | 0.030 |
Why?
|
| Dientamoebiasis | 1 | 2013 | 4 | 0.030 |
Why?
|
| Mebendazole | 1 | 2013 | 7 | 0.030 |
Why?
|
| Toxoplasmosis | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cryptosporidiosis | 1 | 2013 | 41 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 304 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1108 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2013 | 236 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1586 | 0.020 |
Why?
|
| Chagas Disease | 1 | 2013 | 294 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 12469 | 0.010 |
Why?
|